REVVITY, INC.
RVTYAPI behind this page
RVTY Q2 2025 request
Playground key active
/api/financials?ticker=RVTY&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 720,284 | 691,685 | +4.1% |
Show Product Lines breakouts |
|||
| Product | 610,704 | 589,091 | +3.7% |
| Service | 109,580 | 102,594 | +6.8% |
Show Business Segments breakouts |
|||
| Diagnostics [Member] | 354,386 | 343,160 | +3.3% |
| Diagnostics [Member] · Americas | 126,509 | 117,993 | +7.2% |
| Diagnostics [Member] · Asia | 108,543 | 115,131 | -5.7% |
| Diagnostics [Member] · Europe | 119,334 | 110,036 | +8.4% |
| Diagnostics [Member] · Immunodiagnostics [Member] | 218,818 | 213,252 | +2.6% |
| Diagnostics [Member] · Reportable Segment Revenue [Member] | 354,386 | 343,160 | +3.3% |
| Diagnostics [Member] · Reproductive health [Member] | 135,568 | 129,908 | +4.4% |
| Life Sciences [Member] | 365,898 | 348,525 | +5.0% |
| Life Sciences [Member] · Americas | 197,071 | 189,790 | +3.8% |
| Life Sciences [Member] · Asia | 84,529 | 84,183 | +0.4% |
| Life Sciences [Member] · Europe | 84,298 | 74,552 | +13.1% |
| Life Sciences [Member] · Life Sciences Solutions [Member] | 298,052 | 297,782 | +0.1% |
| Life Sciences [Member] · Reportable Segment Revenue [Member] | 365,898 | 348,525 | +5.0% |
| Life Sciences [Member] · Software [Member] | 67,846 | 50,743 | +33.7% |
Show Geography breakouts |
|||
| Americas | 323,580 | 307,783 | +5.1% |
| Asia | 193,072 | 199,314 | -3.1% |
| Europe | 203,632 | 184,588 | +10.3% |
Show Major goods/service lines [Axis] breakouts |
|||
| Immunodiagnostics [Member] | 218,818 | 213,252 | +2.6% |
| Life Sciences Solutions [Member] | 298,052 | 297,782 | +0.1% |
| Reproductive health [Member] | 135,568 | 129,908 | +4.4% |
| Software [Member] | 67,846 | 50,743 | +33.7% |
Show Segment Reporting [Axis] breakouts |
|||
| Reportable Segment Revenue [Member] | 720,284 | 691,685 | +4.1% |
| Cost of Revenue | 327,728 | 306,179 | +7.0% |
Show Product Lines breakouts |
|||
| Product | 285,593 | 262,936 | +8.6% |
| Service | 42,135 | 43,243 | -2.6% |
| Selling, General & Administrative | 248,526 | 251,650 | -1.2% |
| Research & Development | 53,270 | 48,132 | +10.7% |
| Operating Income | 90,760 | 85,724 | +5.9% |
| Interest And Other Expense Net | 22,110 | -938 | +2457.1% |
| Income Before Taxes | 68,650 | 86,662 | -20.8% |
| Income Tax Expense (Benefit) | 13,428 | 14,056 | -4.5% |
| Income Loss From Continuing Operations | 55,222 | 72,606 | -23.9% |
| Income Loss From Discontinued Operations Net Of Tax | -1,274 | -17,246 | +92.6% |
| Net Income | 53,948 | 55,360 | -2.6% |
Show Equity Components breakouts |
|||
| Retained Earnings | 53,948 | 55,360 | -2.6% |
| Income Loss From Continuing Operations Per Basic Share | 0.47 | 0.59 | -20.3% |
| Income Loss From Discontinued Operations Net Of Tax Per Basic Share | -0.01 | -0.14 | +92.9% |
| EPS (Basic) | 0.46 | 0.45 | +2.2% |
| Income Loss From Continuing Operations Per Diluted Share | 0.47 | 0.59 | -20.3% |
| Income Loss From Discontinued Operations Net Of Tax Per Diluted Share | -0.01 | -0.14 | +92.9% |
| EPS (Diluted) | 0.46 | 0.45 | +2.2% |
| Wtd Avg Shares (Basic) | 117,512 | 123,354 | -4.7% |
| Wtd Avg Shares (Diluted) | 117,538 | 123,477 | -4.8% |
| Non-Operating Income (Expense) | 22,110 | -938 | +2457.1% |
| Interest Expense | 22,937 | 24,717 | -7.2% |
| Interest Income | -8,345 | -20,512 | +59.3% |
| Comprehensive Income | 212,922 | 38,780 | +449.1% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 991,849 | 1,248,120 | -20.5% |
| Accounts Receivable | 661,138 | 597,436 | +10.7% |
| Inventory | 388,467 | 401,432 | -3.2% |
| Other Assets Current | 194,729 | 205,631 | -5.3% |
| Total Current Assets | 2,236,183 | 3,158,689 | -29.2% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 499,026 | 503,119 | -0.8% |
| Operating Lease Right-of-Use Assets | 177,168 | 143,789 | +23.2% |
| Goodwill | 6,614,989 | 6,496,971 | +1.8% |
Show Business Segments breakouts |
|||
| Diagnostics [Member] | 1,967,069 | — | — |
| Life Sciences [Member] | 4,647,920 | — | — |
| Other Non-Current Assets | 321,055 | 296,794 | +8.2% |
| Total Assets | 12,362,789 | 13,424,849 | -7.9% |
| Intangible Assets | 2,514,368 | 2,825,487 | -11.0% |
Show Finite and Indefinite Lived Intangible Assets by Major Class [Axis] breakouts |
|||
| Core Technology [Member] | 775,517 | — | — |
| Customer Relationships | 1,676,198 | — | — |
| Licensing Agreements | 8,347 | — | — |
| Patents | 1,394 | — | — |
| Trade Names And Trademarks [Member] | 52,912 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 2,514,368 | 2,825,487 | -11.0% |
| Current Liabilities | |||
| Current Portion of Long-Term Debt | 230 | — | — |
| Accounts Payable | 178,151 | 174,871 | +1.9% |
| Accrued Liabilities | 493,433 | 503,728 | -2.0% |
| Total Current Liabilities | 671,814 | 1,390,013 | -51.7% |
| Non-Current Liabilities | |||
| Long-Term Debt | 3,214,324 | 3,162,600 | +1.6% |
| Other Non-Current Liabilities | 760,178 | 878,788 | -13.5% |
| Operating Lease Liabilities | 160,305 | 123,134 | +30.2% |
| Total Liabilities | 4,806,621 | 5,554,535 | -13.5% |
| Long-Term Debt (Q) | — | — | — |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 | 3,214,324 | 3,162,600 | +1.6% |
| Fair Value Inputs Level2 · 1.875 Percent Ten Year Senior Unsecured Notes [Member] | 584,577 | — | — |
| Fair Value Inputs Level2 · 1.900% Senior Unsecured Notes due 2028 [Member] | 497,731 | — | — |
| Fair Value Inputs Level2 · 2.250% Senior Unsecured Notes due in 2031 [Member] | 496,164 | — | — |
| Fair Value Inputs Level2 · 2.55 Percent Senior Unsecured Notes due in 2031 [Member] | 397,801 | — | — |
| Fair Value Inputs Level2 · 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | 845,083 | — | — |
| Fair Value Inputs Level2 · 3.625 Percent Senior Unsecured Notes due in 2051 [Member] | 395,990 | — | — |
| Fair Value Inputs Level2 · Senior Unsecured Notes [Member] | 3,217.3 | — | — |
Show Debt Instrument breakouts |
|||
| Line of Credit, Maturing January 7, 2030 | 3,213 | — | — |
| Stockholders' Equity | |||
| Common Stock | 116,331 | 123,368 | -5.7% |
| Additional Paid In Capital Common Stock | 1,672,216 | 2,415,583 | -30.8% |
| Retained Earnings | 5,925,098 | 5,673,297 | +4.4% |
| Accumulated Other Comprehensive Income | -157,477 | -341,934 | +53.9% |
| Total Stockholders' Equity | 7,556,168 | 7,870,314 | -4.0% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -157,477 | -341,934 | +53.9% |
| Additional Paid In Capital | 1,672,216 | 2,415,583 | -30.8% |
| Common Stock | 116,331 | 123,368 | -5.7% |
| Retained Earnings | 5,925,098 | 5,673,297 | +4.4% |
| Total Liabilities & Equity | 12,362,789 | 13,424,849 | -7.9% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Restructuring Chargesand Changesin Estimates | 14,442 | 22,201 | -34.9% |
| Depreciation & Amortization | 200,200 | 215,146 | -6.9% |
| Stock-Based Compensation | 17,864 | 22,218 | -19.6% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -166 | 6,349 | -102.6% |
| Amortization Of Financing Costs And Discounts | 2,320 | 3,509 | -33.9% |
| Change In Fair Value Of Financial Securities | -1,118 | -6,971 | +84.0% |
| Foreign Currency Transaction Gain Loss Unrealized | 140 | -857 | +116.3% |
| Change in Accounts Receivable | -21,901 | 28,194 | -177.7% |
| Change in Inventory | 5,642 | 17,251 | -67.3% |
| Change in Accounts Payable | 3,278 | -22,974 | +114.3% |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -49,177 | -52,894 | +7.0% |
| Net Cash Provided By Used In Operating Activities Continuing Operations | 268,415 | 332,474 | -19.3% |
| Cash Provided By Used In Operating Activities Discontinued Operations | -5,942 | -26,290 | +77.4% |
| Net Cash from Operations | 262,473 | 306,184 | -14.3% |
| Investing Activities | |||
| Capital Expenditures | -34,850 | -39,875 | +12.6% |
| Proceeds From Divestiture Of Businesses | 229 | — | — |
| Net Cash Provided By Used In Investing Activities Continuing Operations | -34,621 | -44,212 | +21.7% |
| Cash Provided By Used In Investing Activities Discontinued Operations | 18,750 | 147,522 | -87.3% |
| Net Cash from Investing | -15,871 | 103,310 | -115.4% |
| Financing Activities | |||
| Debt Issuance Costs | -2,474 | — | — |
| Proceeds From Repayments Of Other Debt | -103 | -11,200 | +99.1% |
| Payment For Contingent Consideration Liability Financing Activities | -1,978 | -8,749 | +77.4% |
| Proceeds From Stock Options Exercised | 2,632 | 6,032 | -56.4% |
| Share Repurchases | -447,501 | -30,309 | -1376.5% |
| Payments Of Dividends Common Stock | -16,715 | -17,282 | +3.3% |
| Net Cash from Financing | -466,139 | -61,508 | -657.9% |
| Supplemental | |||
| Restricted Cash Current | 1,141 | 1,308 | -12.8% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 48,075 | -12,931 | +471.8% |
| Net Change in Cash | -171,462 | 335,055 | -151.2% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 992,990 | 1,249,428 | -20.5% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.